Researchers to present progression-free survival results
Results from the final analysis of progression-free survival, response rate, and safety for the randomized, phase III Breast Cancer Trials of Oral Everolimus-1 (BOLERO-1) are to be presented here at the 2014 San Antonio Breast ...
Dec 15, 2014
0
0